Clinical trials: Contrast Induced Nephropathy
Kidney Diseases, Diabetes Mellitus
Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy
The aim of this prospective, randomized, controlled study is to investigate the effect of pretreatment with intravenous Alprostadil on the incidence of CIN in a high-risk population of patients with both type 2 diabetes mellitus…
- Conditions
- Kidney Diseases, Diabetes Mellitus, Acute Kidney Injury, Kidney Failure, Chronic
- Trial name
- NCT01722513
- Testing
- Alprostadil ﹠control
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shanghai 10th People's Hospital
Acute Kidney Injury, Renal Insufficiency
Novel Biomarkers for Risk Prediction of Contrast-Induced Acute Kidney Injury Post Coronary Angiography
Contrast-induced acute kidney injury (CI-AKI) has been recognized as the third most common cause of hospital acquired AKI, after hypotension-associated hypo-perfusion and post-operative AKI.
- Conditions
- Acute Kidney Injury, Renal Insufficiency, Kidney Diseases
- Trial name
- NORDICA (NCT02263820)
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Sapere Bio
Kidney Failure, Acute, Contrast Media
Bicarbonate v Saline to Prevent Contrast Nephropathy
Slowing of kidney function occurs in a minority of people given dye during angiography. The purpose of this study is to compare two different types of fluid given into a vein to reduce the risk of kidney injury: salt in water or…
- Trial name
- NCT00384995
- Testing
- 0.9% (154 mEq/L) IV Sodium Chloride, 1/6 M (166 mEq/L) IV Sodium Bicarbonate
- Where
- 5 sites in Italy
- Volunteers
- 61 people
- Sponsor
- Italian Society of Nephrology
Contrast-Induced Nephropathy
High Dose Atorvastatin for Preventing Contrast-induced Nephropathy
The aim of this study is to determine the efficacy of atorvastatin in the prevention of contrast-induced nephropathy in patients undergoing computed tomography coronary angiography.
- Trial name
- NCT02114346
- Testing
- Atorvastatin, 0.9% sodium chloride
- Where
- Iran
- Volunteers
- 250 people
- Sponsor
- Isfahan University of Medical Sciences
Contrast Induced Nephropathy, Metabolic Syndrome
Metabolic Syndrome and Contrast Induced Nephropathy
Prevention of contrast induced nephropathy after interventional cardiologic procedures deserves close interest because of its association with prolonged hospitalization, increased cost and increased in hospital and long term…
- Trial name
- NCT02192372
- Where
- Turkey (Türkiye)
- Volunteers
- 599 people
- Sponsor
- Ankara University
Myocardial Infarction
Myocardial Salvage and Contrast Dye Induced Nephropathy Reduction by N-Acetylcystein
Acetylcystein is a potent antioxidans which is able to prevent contrast dye induced nephropathy in stable patients undergoing additional hydration. In primary percutaneous intervention for infarction hydration is not possible.
- Trial name
- LIPSIA-N-ACC (NCT00463749)
- Testing
- Acetylcystein
- Where
- Germany
- Volunteers
- 251 people
- Sponsor
- University of Leipzig
Renal Insufficiency
Renal Safety Evaluation After Dotarem®-Enhanced MRI
Although there is a well documented risk of acute renal failure with the iodinated contrast agents, the implication of intravenous gadolinium-based contrast agents in nephrotoxicity remains controversial.
- Trial name
- RESCUE (NCT00650845)
- Testing
- Dotarem®-enhanced MRI, non-enhanced MRI
- Where
- 15 sites in Belgium, France and 2 more
- Volunteers
- 135 people
- Sponsor
- Guerbet
Nephropathy, Oxidative Stress
Polymorphism of Oxidative Stress Genes in the Pathogenesis and Antioxidant Prevention of Contrast Induced Nephropathy
With the wide use of contrast agents in clinical diagnosis and treatment, contrast induced nephropathy(CIN) accounts for 1/3 of hospital acquired acute renal failure.The mortality rate of patients with CIN is up to 35%,and about…
- Trial name
- NCT01142024
- Testing
- Glutathione, saline
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Huashan Hospital
Cardio-Renal Syndrome
Contrast-induced Nephropathy: Incidence,Risk Factors,Effective Prevention and Management Method
This review article have included about ten thousand patients undergoing percutaneous coronary intervention (PCI), aim to identify the incidence of CIN in actual, find some new risk factors and the protecting methods for these…
- Trial name
- NCT02664246
- Testing
- percutaneous coronary intervention
- Volunteers
- 10,000 people
- Sponsor
- Chinese PLA General Hospital
Chronic Kidney Disease
Efficacy Trial of N-Acetylcysteine and Sodium Bicarbonate for the Prevention of Contrast-Induced Acute Kidney Injury
Contrast-Induced Acute Kidney Injury(CIAKI) was defined as an absolute increase in serum creatinine of more than or equal to 0.3mg/dl (≥ 26.4 μmol/l), a percentage increase in serum creatinine of more than or equal to 50%…
- Trial name
- PREKIT (NCT01210456)
- Testing
- Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate
- Where
- Japan
- Volunteers
- 458 people
- Sponsor
- Tokushukai Medical Group
Aortic Aneurysm, Ischemic Preconditioning
Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR
Introduction: Contrast induced nephropathy (CIN) is a major inconvenience in the use of iodinated contrast media (ICM) and it is associated with a significant increase in morbimortality and cost of hospitalization.
- Trial name
- RIPC-EVAR (NCT05350683)
- Testing
- Remote ischemic preconditioning
- Where
- Spain
- Volunteers
- 120 people
- Sponsor
- Vascular Investigation Network Spanish Society for Angiology and Vascular Surgery
Acute Kidney Injury
Efficacy and Safety of Deferiprone in Patients With Chronic Kidney Disease Undergoing a Cardiac Catheterization and Receiving Contrast Agent
This trial will evaluate whether treatment with CRMD001 (unique formulations of the iron chelator, Deferiprone) will reduce morbidity and mortality in subjects with Chronic Kidney Disease (CKD) and additional risk factors.
- Trial name
- NCT01391520
- Testing
- deferiprone
- Sponsor
- CorMedix Therapeutics
Heart Failure Acute, Renal Dysfunction
Contrast-Induced Acute Kidney Injury Prevention in Acute Heart Failure
The K-PROSE study is a randomized clinical investigation evaluating strategies to prevent contrast-induced acute kidney injury (CI-AKI) in patients hospitalized with acute heart failure and moderate renal dysfunction (eGFR 30-75…
- Trial name
- K-PROSE (NCT07550790)
- Testing
- Furosemide, 0.9 % Normal Saline
- Where
- South Korea
- Volunteers
- 190 people
- Sponsor
- Jin Joo Park
Acute ST Segment Elevation Myocardial Infarction
Effects of N-acetyl Cysteine During Primary Percutaneous Coronary Intervention
The aim of this study is to evaluate the effects of N-acetyl cysteine on major cardiac and cerebral events in patients undergoing primary percutaneous coronary intervention who have moderate to high risk for contrast induced…
- Trial name
- EASE-PRM-PCI (NCT01878344)
- Testing
- NAC, Saline
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people
- Sponsor
- Suleyman Demirel University
AKI, Contrast-induced Nephropathy
Establishing Clinical Utility of a New Diagnostic Test in Patients Undergoing Cardiac Catheterization
This study will collect high-quality randomized controlled data across the U.S. from practicing cardiologists performing invasive/interventional procedures and determine how they currently manage patients at risk for CIN and how…
- Trial name
- NCT04266834
- Testing
- Experimental Arm
- Where
- United States
- Volunteers
- 157 people, healthy volunteers welcome
- Sponsor
- Qure Healthcare, LLC
Contrast-induced Acute Kidney Injury, Acute Coronary Syndromes
DyeVert System and Contrast-induced Acute Kidney Injury
The aim of the REnal Insufficiency Following Contrast MEDIA Administration TriaL IV (REMEDIAL IV) is to test whether the use of the DyeVert system is effective in reducing CI-AKI rate in ACS patients undergoing urgent/immediate…
- Trial name
- REMEDIALIV (NCT04714736)
- Testing
- Coronary angiography using DyeVert system, Coronary angiography using conventional manual injection syringe.
- Where
- 2 sites in Italy
- Volunteers
- 522 people
- Sponsor
- Clinica Mediterranea
Chronic Kidney Failure
Improved Estimation of GFR by Cystatin C in Preventing Contrast Induced Nephropathy by NAC or Zn
Background Prevention of contrast media (CM) induced nephropathy (CIN) by pharmacological prophylaxis (e.g. N-acetylcysteine; NAC) is controversially discussed.
- Trial name
- NCT00399256
- Testing
- Acetylcysteine, Zinc
- Where
- Germany
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)
Radiocontrast-induced Nephropathy
Mechanisms for the Effect of Acetylcysteine on Renal Function After Exposure to Radiographic Contrast Material
Millions of people receive radiographic contrast material for investigations like CT and coronary angiography. While considered safe in healthy patients, it can cause acute renal impairment.
- Trial name
- NCT00558142
- Testing
- Acetylcysteine, Visipaque 320
- Where
- United Kingdom
- Volunteers
- 107 people, healthy volunteers welcome
- Sponsor
- University of Edinburgh
Acute Kidney Injury
Double-Blind Placebo-Controlled CIN Trial
This double-blinded placebo-controlled study will examine the incidence and significance of contrast-induced acute kidney injury following IV iodine-based contrast material administration in subjects with stage IIIB or stage IV…
- Trial name
- NCT02467075
- Testing
- Iopamidol 300 (Contrast)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Michigan
Radiographic Contrast Agent Nephropathy
Does Bicarbonate in Addition to Theophylline Reduce CIN?
Contrast-induced nephropathy (CIN) is the third most frequent cause of hospital-acquired acute renal failure. Different regimes in the prophylaxis of CIN have been investigated in the last years.
- Trial name
- NCT02643602
- Testing
- Hydration with bicarbonate in addition to theophylline, Hydration with sodium chloride in addition to theophylline
- Volunteers
- 152 people
- Sponsor
- Technical University of Munich